In response to Fuzzyjr's post. The "market" isn't going to be prescribing apabetalone. The cardiologists, endocrinologists and other medical doctors attending these cardiovascular and diabetes conferences will be the ones prescribing apabetalone. If and when apabetalone clears Phase 3 and is applying for EMA and FDA approval, why would any doctors prescribe it if they have never heard of it? Do you expect Resverlogix to just wait until the trial is nearly complete before attending conferences again? You've got to plant the seeds now if you expect anything to grow in the future. Remember that apabetalone is a first in class BD2 selective BET bromodomain inhibitor. Chances are very few docs are very familiar with epigenetic drugs in clinical trials, especially the BET inhibitors. If they have heard of it, they may only remember that apabetalone is an apoAI/HDL modulating drug that failed its ASSURE Phase 2 trial. Some clinicians may even falsely associate apabetalone with the failed CETP inhibitors. There are other therapies in the space right now for alleviating cardiovascular risk in diabetes, so why should these clinicians actively seek out what therapies may be on the horizon? This is why it is so important to have a presence at these scientific meetings. I don't understand how one can be upset about key opinion leaders in the field presenting at the largest cardiovascular conference in the world on the lead drug of a company you're invested in. If you want the stock to sell, you also have to make sure your product is known to those who will be prescribing it. Furthermore, with so many of the study sites for BETonMACE being in Europe, and BETonMACE still in the early phases of recruitment (~600 of 2400 enrolled), the clinicians who are running these study sites need to be/stay informed. It is the "European" Society of Cardiology conference. If you're not appearing, you're disappearing.

BearDownAZ